Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTOplus Met XR in oral cavity or oropharynx cancer
NCT02917629Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pioglitazone in oral cavity squamous cell carcinoma (OCSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by National Cancer Institute. Started May 2018; status: terminated.
02
Drugs
pioglitazone
03
Conditions
oral cavity squamous cell carcinoma (OCSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT02917629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917629.